Evidence map›Paper›PMID 30421091›Full record

ArticlePharmaceutical research2018

An Expandable Mechanopharmaceutical Device (1): Measuring the Cargo Capacity of Macrophages in a Living Organism.

Phillip Rzeczycki, Tehetina Woldemichael, Andrew Willmer, Mikhail D Murashov, Jason Baik, Rahul Keswani, Gi Sang Yoon, Kathleen A Stringer, Nair Rodriguez-Hornedo, Gus R Rosania

Abstract read
In one paragraph

Article in Pharmaceutical research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Molecular design of a pathogen activated, self-assembling mechanopharmaceutical device.Journal of controlled release : official journal of the Controlled Release Society · 2022
    Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Phillip RzeczyckiDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI, 48109, USA.
Tehetina WoldemichaelBiophysics Program, College of Literature, Science, and the Arts, University of Michigan, Ann Arbor, MI, USA.
Andrew WillmerDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI, 48109, USA.
Mikhail D MurashovDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI, 48109, USA.
Jason BaikDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI, 48109, USA.
Rahul KeswaniDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI, 48109, USA.
Gi Sang YoonDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI, 48109, USA.
Kathleen A StringerDepartment of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, MI, USA.
Nair Rodriguez-HornedoDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI, 48109, USA.
Gus R RosaniaDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI, 48109, USA. grosania@umich.edu.
University of Michigan–Ann Arbor · US

Funding

Chemical Address Tags: A Cheminformatics & Image Data Management and Analysis Plan - SupplementR01GM078200 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ROSANIA, GUS R · 2006 to 2015
$4.2M
L-Carnitine Pharmacometabolomics in Sepsis (CaPS)R01GM111400 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI STRINGER, KATHLEEN A · 2016 to 2019
$1.2M
National Institutes of Health R01GM078200NIGMS NIH HHS R01 GM078200NIGMS NIH HHS R01 GM111400
6 · The paper itself

Abstract

purposeClofazimine (CFZ) is an FDA-approved, poorly soluble small molecule drug that precipitates as crystal-like drug inclusions (CLDIs) which accumulate in acidic cytoplasmic organelles of macrophages. In this study, we considered CLDIs as an expandable mechanopharmaceutical device, to study how macrophages respond to an increasingly massive load of endophagolysosomal cargo.

methodsFirst, we experimentally tested how the accumulation of CFZ in CLDIs impacted different immune cell subpopulations of different organs. Second, to further investigate the mechanism of CLDI formation, we asked whether specific accumulation of CFZ hydrochloride crystals in lysosomes could be explained as a passive, thermodynamic equilibrium phenomenon. A cellular pharmacokinetic model was constructed, simulating CFZ accumulation driven by pH-dependent ion trapping of the protonated drug in the acidic lysosomes, followed by the precipitation of CFZ hydrochloride salt via a common ion effect caused by high chloride concentrations.

resultsWhile lower loads of CFZ were mostly accommodated in lung macrophages, increased CFZ loading was accompanied by organ-specific changes in macrophage numbers, size and intracellular membrane architecture, maximizing the cargo storage capabilities. With increasing loads, the total cargo mass and concentrations of CFZ in different organs diverged, while that of individual macrophages converged. The simulation results support the notion that the proton and chloride ion concentrations of macrophage lysosomes are sufficient to drive the massive, cell type-selective accumulation and growth of CFZ hydrochloride biocrystals.

conclusionCLDIs effectively function as an expandable mechanopharmaceutical device, revealing the coordinated response of the macrophage population to an increasingly massive, whole-organism endophagolysosomal cargo load.

Indexed as

AnimalsAnti-Bacterial AgentsBiological TransportCell LineCell MembraneClofazimineComputer SimulationDrug CarriersDrug LiberationHumansHydrogen-Ion ConcentrationLiverMacrophagesMaleMice, Inbred C57BLModels, BiologicalAnti-Bacterial AgentsClofazimineDrug CarriersSesame OilSolventsclofazimine self-assemblydrug deliverylysosomepharmacokineticsvolume of distribution

Identifiers

PMID30421091
PMCPMC6501569
OpenAlexW2900732721

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.